Design of Cilostazol Nanocrystals for Improved Solubility

  • Jin-Seok ChoiEmail author
Original Article



The purpose of this study is to achieve enhanced solubility of cilostazol (CLT) by nanocrystal (NC) formation. CLT-NC was prepared by nanoprecipitation without the use of surfactant.


To optimize particle size, we controlled four parameters, including the speed or power in the homogenizer or probe-sonicator, respectively, the processing temperature, drug concentration, and collection method. CLT-NC with a mean size of 500–600 nm was successfully prepared by a simple method.


The small particle size was optimized by probe-sonication (200 W) at a low temperature (4 °C), drug concentration (4 mg/mL), and filtration (collecting method). The DSC thermograms and crystallinity of CLT exhibited a slight shift of on CLT-NC. The solubility of CLT-NC significantly increased 10.7-/7.6-/10.0-fold compared with that of CLT in different media (distilled water (DW), pH 1.2 and pH 6.8 buffers, respectively) for 24 h. Moreover, CLT-NC did not show the toxicity characteristic of CLT in the Caco-2 cells, and the nanocrystals were well maintained in 25 °C and 4 °C for 3 months.


We developed CLT-NC with high solubility and non-toxic characteristics, which is expected to have high bioavailability in animals.


Cilostazol Nanocrystal Solubility Cytotoxicity Stability 







Field emission scanning electron microscopy


Differential scanning calorimetry


X-ray diffraction


Distilled water



This work was supported by a research program funded by Chodang University in 2018.

Compliance with Ethical Standards

Conflict of Interest

The author declares that there are no conflicts of interest.


  1. 1.
    Choi J-S, Lee S-E, Jang WS, Byeon JC, Park J-S. Solid dispersion of dutasteride using the solvent evaporation method: approaches to improve dissolution rate and oral bioavailability in rats. Mater Sci Eng C. 2018;90:387–96.CrossRefGoogle Scholar
  2. 2.
    Choi J-S, Park J-S. Design of PVP/VA S-630 based tadalafil solid dispersion to enhance the dissolution rate. Eur J Pharm Sci. 2017;97:269–76.CrossRefGoogle Scholar
  3. 3.
    Choi J-S, Kwon SH, Lee SE, Jang WS, Byeon JC, Jeong HM, et al. Use of acidifier and solubilizer in tadalafil solid dispersion to enhance the in vitro dissolution and oral bioavailability in rats. Int J Pharm. 2017;526:77–87.CrossRefGoogle Scholar
  4. 4.
    Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59:617–30.CrossRefGoogle Scholar
  5. 5.
    Kong X, Zhao Y, Quan P, Fang L. Development of a topical ointment of betamethasone dipropionate loaded nanostructured lipid carrier. Asian J Pharm Sci. 2016;11:248–54.CrossRefGoogle Scholar
  6. 6.
    Zheng X-C, Ren W, Zhang S, Zhong T, Duan X, Yin YF, et al. The theranostic efficiency of tumor-specific, pH-responsive, peptide-modified, liposome-containing paclitaxel and superparamagnetic iron oxide nanoparticles. Int J Nanomedicine. 2018;13:1495–504.CrossRefGoogle Scholar
  7. 7.
    Choi J-S, Cao J, Naeem M, Noh J, Hasan N, Choi HK, et al. Size-controlled biodegradable nanoparticles: preparation and size-dependent cellular uptake and tumor cell growth inhibition. Colloids Surf B: Biointerfaces. 2014;122:545–51.CrossRefGoogle Scholar
  8. 8.
    Choi J-S, Jang WS, Park J-S. Comparison of adsorption and conjugation of Herceptin on poly (lactic-co-glycolic acid) nanoparticles–effect on cell internalization in breast cancer cells. Mater Sci Eng C. 2018;92:496–507.CrossRefGoogle Scholar
  9. 9.
    Park J-J, Meghani N, Choi J-S, Lee B-J. Development and evaluation of decorated aceclofenac nanocrystals. Colloids Surf B: Biointerfaces. 2016;143:206–12.CrossRefGoogle Scholar
  10. 10.
    Sohn JS, Yoon D-S, Sohn JY, Park J-S, Choi J-S. Development and evaluation of targeting ligands surface modified paclitaxel nanocrystals. Mater Sci Eng C. 2017;72:228–37.CrossRefGoogle Scholar
  11. 11.
    Choi J-S, Park J-S. Surface modification of docetaxel nanocrystals with HER2 antibody to enhance cell growth inhibition in breast cancer cells. Colloids Surf B: Biointerfaces. 2017;159:139–50.CrossRefGoogle Scholar
  12. 12.
    Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12:1068–75.CrossRefGoogle Scholar
  13. 13.
    Müller RH, Gohla S, Keck CM. State of the art of nanocrystals–special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 2011;78:1–9.CrossRefGoogle Scholar
  14. 14.
    Jermain SV, Brough C, Williams RO III. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery–an update. Int J Pharm. 2018;535:379–92.CrossRefGoogle Scholar
  15. 15.
    Choi J-S, Park J-S. Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting. Drug Des Devel Ther. 2017;11:17–26.CrossRefGoogle Scholar
  16. 16.
    Choi J-S, Park J-S. Effects of paclitaxel nanocrystals surface charge on cell internalization. Eur J Pharm Sci. 2016;93:90–6.CrossRefGoogle Scholar
  17. 17.
    Jinno J-i, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111:56–64.CrossRefGoogle Scholar
  18. 18.
    Detroja C, Chavhan S, Sawant K. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm. 2011;79:635–52.CrossRefGoogle Scholar
  19. 19.
    Basa S, Muniyappan T, Karatgi P, Prabhu R, Pillai R. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm. 2008;34:1209–18.CrossRefGoogle Scholar
  20. 20.
    Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62:3–16.CrossRefGoogle Scholar
  21. 21.
    Sinha B, Müller RH, Möschwitzer JP. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm. 2013;453:126–41.CrossRefGoogle Scholar
  22. 22.
    Shete G, Pawar YB, Thanki K, Jain S, Bansal AK. Oral bioavailability and pharmacodynamic activity of hesperetin nanocrystals generated using a novel bottom-up technology. Mol Pharm. 2015;12:1158–70.CrossRefGoogle Scholar
  23. 23.
    Jinno J-i, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, et al. In vitro–in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J Control Release. 2008;130:29–37.CrossRefGoogle Scholar
  24. 24.
    Miao X, Sun C, Jiang T, Zheng L, Wang T, Wang S. Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol. J Pharm Pharm Sci. 2011;14:196–214.CrossRefGoogle Scholar
  25. 25.
    Kurien J, Jayasekhar P, John J. HPTLC determination of cilostazol in pharmaceutical dosage forms. Int J Adv Res. 2014;2:952–7.Google Scholar
  26. 26.
    Sarode AL, Wang P, Obara S, Worthen DR. Supersaturation, nucleation, and crystal growth during single-and biphasic dissolution of amorphous solid dispersions: polymer effects and implications for oral bioavailability enhancement of poorly water soluble drugs. Eur J Pharm Biopharm. 2014;86:351–60.CrossRefGoogle Scholar
  27. 27.
    Paarvanova B, Tacheva B, Dospatliev L, Karabaliev M, Ivanov I. Polarity index: a measure for the destabilization effect of organic solutes on erythrocyte membrane proteins. Trakia J Sci. 2012;10:150–4.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical ManagementChodang UniversityMuan-gunSouth Korea

Personalised recommendations